1 Research Article

2 Differentiating COVID-19 and dengue from other febrile illnesses in co-epidemics:

3 Development and internal validation of COVIDENGUE scores

4

Patrick Gérardin¹, Olivier Maillard¹, Léa Bruneau², Frédéric Accot³, Florian Legrand^{3,5}, Patrice
 Poubeau^{3,4,5}, Rodolphe Manaquin^{3,4,5}, Fanny Andry^{3,4,5†}, Antoine Bertolotti^{1,3,4†}, Cécile
 Levin^{3,4,5}

8

9 ¹ Centre for Clinical Investigation - Clinical Epidemiology (CIC 1410), Institut National de la Santé et de

- 10 la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de la Réunion, Saint Pierre,
- 11 Reunion, France
- 12 ² Department of Public health and Research Support, Centre Hospitalier Universitaire de la Réunion,
- 13 Saint Denis, Reunion, France
- ³ COVID-19 testing centre, Centre Hospitalier Universitaire de la Réunion, Saint Pierre, Reunion,
- 15 France
- ⁴ Department of Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de la
- 17 Réunion, Saint Pierre, Reunion, France
- ⁵ City to Hospital Outpatient Clinic for the care of COVID-19, Centre Hospitalier Universitaire de la
- 19 Réunion, Saint Pierre, Reunion, France
- 20
- 21 Corresponding Author: P. Gérardin, Center for Clinical Investigation (CIC1410), CHU
- 22 Réunion, BP 350, 97448 Saint-Pierre Cedex Reunion, (patrick.gerardin@chu-reunion.fr)
- 23 [†] Contributed equally.
- 24 Short running head title: Scores to distinguish COVID-19 from dengue and other febrile
- 25 illnesses in co-epidemics

26 Abstract

27

Background. In a retrospective cohort study, we previously distinguished the factors associated with
 coronavirus 2019 (COVID-19) or dengue from those associated with other febrile illnesses (OFIs). In
 this study, we developed a scoring system to discriminate both infectious diseases.

31

Methods. Predictors of both infections were sought using multinomial logistic regression models (OFIs as controls) in all subjects suspected of COVID-19 who attended the SARS-CoV-2 testing center of Saint-Pierre teaching hospital, Reunion Island, between March 23 and May 10, 2020. Two COVIDENGUE scores were developed and internally validated by bootstrapping for predicting each infection after weighting the odd ratios according to a predefined rule. The discriminative ability of each score was assessed using the area under the receiver operating characteristic curve (AUC). Their calibration was assessed using goodness-of-fit statistics.

39

40 Results. Over 49 days, 80 COVID-19, 60 non-severe dengue and 872 OFI cases were diagnosed. The 41 translation of the best fit model yielded two COVIDENGUE scores composed of 11 criteria: contact 42 with a COVID-19 positive case (+3 points for COVID-19; 0 point for dengue), return from travel 43 abroad within 15 days (+3/-1), previous individual episode of dengue (+1/+3), active smoking (-3/0), 44 body ache (0/+5), cough (0/-2), upper respiratory tract infection symptoms (-1/-1), anosmia (+7/-1), 45 headache (0/+5), retro-orbital pain (-1/+5), and delayed presentation (>3 days) to hospital (+1/0). 46 The AUC was of 0.79 (95%CI 0.76-0.82) for COVID-19 score and of 0.88 (95%CI 0.85-0.90) for dengue 47 score. Calibration was satisfactory for COVID-19 score and excellent for dengue score. For predicting 48 COVID-19, sensitivity was of 97% at the 0-point cut-off and specificity approximated 99% at the 10-49 point cut-off. For predicting dengue, sensitivity approximated 97% at the 3-point cut-off and 50 specificity 98% at the 11-point cut-off.

51 Conclusions. In conclusion, the COVIDENGUE scores proved discriminant to differentiate COVID-19

52 and dengue from other febrile illnesses in the context of SARS-CoV-2 testing center during a co-

53 epidemic. Further studies are needed to validate or refine these scores in other settings.

54

55

56 Author Summary

57 In the last two years, several countries not only have faced the impact of the coronavirus 2019 (COVID-19) but also dengue epidemics simultaneously, evoking an overburden to healthcare 58 59 systems. On Reunion Island, southwestern Indian ocean, dengue virus is circulating since 2004 under 60 an endemo-epidemic pattern with outbreaks peaking between March and May and has prominently 61 intensified annually since 2015. Regarding COVID-19, Severe Acute Respiratory Syndrome 62 Coronavirus-2 (SARS-CoV-2) emerged in March 2020 and was brought from the Bahamas to the 63 island. COVID-19 and dengue have been deemed clinically similar, especially within the first two days 64 from symptom onset. In the framework of a cohort study conducted at a SARS-CoV-2 testing center 65 between March 23 and May 10, 2020, we developed two scores aimed at predicting both infections. 66 The discriminative ability (the ability to diagnose each infection) was satisfactory to good for COVID-67 19 (area under receiver operating characteristic curve [AUC] 0.79, 95% confidence interval [CI] 0.76-68 0.82) and good for dengue (AUC 0.88, 95%Cl 0.85-0.90). The calibration (the adequacy between 69 predicted and observed infections) was satisfactory for both scores. Each score was user-friendly and 70 provided an easy guidance for predictive analysis, whether in strategies maximizing the prediction or 71 the exclusion of each infection.

72

73 Keywords: coronavirus; COVID-19; severe acute respiratory syndrome; SARS-CoV-2; dengue;
74 arbovirus; flavivirus; epidemics; pandemics; cohort study; risk factors; multivariate analysis; logistic
75 regression; multinomial logistic regression; prediction model; score

76

77 Background

Prompt identification and management of overlapping COVID-19 and dengue infections may prevent cases of both viral diseases from deteriorating [1]. Moreover, it can avoid events of hospitalization in the Intensive Care Unit (ICU) and nosocomial transmission of both infections which may be useful whenever syndemics stress healthcare systems [2]. For public health, more rapid quarantine, contact tracing and vector control measures may help to mitigate the dynamics of both epidemics [2,3].

83 Since Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) spread globally, several 84 countries have been facing dengue epidemics with the fear of increased mortality in the most 85 vulnerable populations [4]. Moreover, the absence of both highly sensitive and specific rapid 86 diagnostics tests may have hampered discrimination between the two separate diagnoses possibly 87 leading to misdiagnoses and the implementation of inadequate countermeasures in emergency 88 situations [4]. On Reunion Island, a French overseas territory located in the southwestern Indian 89 ocean region known to have host one of the largest chikungunya outbreaks [5], dengue virus (DENV) 90 is endemic with annual epidemics occurring since 2015 [6]. Moreover COVID-19, which emerged in 91 March 2020, has established an autochthonous transmission since August 2020 [7].

Surprisingly, most prediction models in the field of COVID-19 research have been dedicated to prognosis and not to the identification of people diseased from infection nor at risk of being infected [8]. Given that differential diagnosis between COVID-19 and dengue was difficult, we set-up a cohort study and developed a multinomial logistic regression model (MLR) aimed at distinguishing SARS-CoV-2 or DENV infections from other febrile illnesses (OFIs) during the first COVID-19 introductive pandemic wave [9].

Herein, we furthered our previous reflection to improve the predictive capability of our model
in testing the hypothesis that the more variables included in the model, the better the discrimination
between the diseases [10].

101 The objective of this study was to develop and internally validate a scoring system able to 102 predict both infectious diseases which to date had never been performed.

103 Methods

104 Study design, study setting and population

105 A retrospective cohort study was conducted using prospectively collected data between 23 March 106 and 10 May 2020, on all participants screened for COVID-19 within the UDACS (Unité de Dépistage 107 Ambulatoire du COVID-19 Sud) of Saint-Pierre which is one of the two SARS-CoV-2 testing centers of 108 the Centre Hospitalier Universitaire Réunion (CHU Reunion) providing care for the general population 109 at the time. People without symptoms or with co-infections were excluded from the study. 110 Consecutively arriving outpatients to the SARS-CoV-2 testing center were informed of the 111 study both verbally and by means of an informational document. Adults, as well as children under 112 the age of 18 years (having the additional verbal consent of their parent or legal guardian) who 113 expressed no opposition were asked to answer a questionnaire and were personally interviewed by a

114 nurse in accordance with the French legislation on bioethics for retrospective research.

Patients' medical records were retrospectively reviewed and anonymized data were collected in standardized forms according to the MR-004 procedure of the *Commission Nationale de l'Informatique et des Libertés* (the French Information Protection Commission). The ethical character of this study on previously collected data was approved by the Scientific Committee for COVID-19 research of CHU Reunion and anonymized data were registered on the Health Data Hub (N° F20201021104344/October, 2020).

121

122 Data collection and gold standard procedure

The questionnaire included information on: i) demographics (gender and age), ii) occupation, iii) risk factors (smoking, obesity, return from travel abroad during the 15 previous days), iv) comorbidities (diabetes, hypertension, cardiovascular disease, chronic obstructive pulmonary disease, cancer, previous episode of dengue and "other comorbidities"), v) intra-household and individual exposure to SARS-CoV-2, vi) individual symptoms (fever, cough, dyspnea/shortness of breath, body aches, diarrhea, gut symptoms, ageusia, metallic taste, anosmia, fatigue, headache, retro-orbital pain and

medRxiv preprint doi: https://doi.org/10.1101/2021.10.14.21264897; this version posted October 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

upper respiratory tract infection symptoms) and vii) treatment (antihypertensive drugs and/or
hydroxychloroquine). Patients' temperature, pulse rate, respiratory rate, and oxygen saturation
(SpO₂) were also measured during the consultation, as well as the presence of cough and/or anxiety.
People reporting symptoms were examined by a medical resident or a senior infectious disease
specialist in accordance with routine care procedures.

134 All participants were screened for COVID-19 by a nurse using a nasopharyngeal swab for 20 135 seconds in one nostril [11]. Each sample was administered for a SARS-CoV-2 reverse transcriptionpolymerase chain reaction (RT-PCR) using the Allplex 2019-nCov[™] assay (Seegene, Seoul, Republic of 136 137 Korea) or an in-house kit (CNR Pasteur) targeting N, RdRP and E genes, or N and IP2/IP4 targets of 138 RdRP depending on which assay was used. Moreover, each participant of the study that was suspected of having dengue was tested for NS1 antigen using an OnSite[™] Duo dengue Ag-IgG-IgM 139 140 rapid diagnostic test (CTK Biotech, San Diego, CA, USA). If these patients had a negative result, they 141 were explored further with a DENV RT-PCR or a dengue serology panel according to the timing of 142 symptoms.

143

144 Statistical analysis

Proportions between COVID-19, dengue, and non-COVID-19 non-dengue OFI patients were compared using Chi square or Fisher exact tests, where deemed appropriate. Bivariable and multivariable multinomial logistic regression (MLR) models were fitted within Stata14[®] (Statacorp, College Station, Texas, USA) to identify independent predictors of COVID-19 and dengue using OFIs as controls.

The first step of the process included fitting a full MLR model with all significant covariates identified by bivariable analysis [9]. From the candidate predictors, we used a backward stepwise selection procedure to drop out non-significant variables (output if *P*>0.05). At this second step, we built a parsimonious MLR model with all significant predictors. In this model, an adaption of the Hosmer-Lemeshow goodness-of-fit chi2 test was used for MLR models with polytomous categorical

outcomes [12] (hereafter named MHL test for multinomial Hosmer-Lemeshow) to minimize the discrepancy between predicted and observed events. In these analyses, crude, and adjusted odds ratios (OR) and 95% confidence intervals (95% CI) were assessed using the binomial and Cornfield methods respectively.

159 Based on the assumption that if there are more variables, there will be better discrimination

160 [10], we added variables that were ruled out at the borderline of significance during the backward

161 stepwise elimination process to our previous 9-covariate parsimonious model [9].

162 The strategy of this third step is detailed in the text file S1.

163 Weighted analyses on the overall inverse probability of hospitalization to assess the potential 164 for selection bias and to test the robustness of the identified predictors were performed next.

Lastly, from the best fit MLR compromise model, we derived two simple scores, the COVIDENGUE scores (one for COVID-19 and, one for dengue) after weighting the OR according to a predefined rule (S1 Table). This rule gave a weight to all the model covariates (no matter their significance) to maximize the possible combinations and to provide the largest range of values which,

169 theoretically, enables the best discrimination.

170 The discriminative ability of the models and of the COVIDENGUE scores (*i.e.*, the model and 171 score performances) for the diagnosis of COVID-19 and dengue were tested using receiver operating 172 characteristic (ROC) plot analyses which considers ROC plots and areas under ROC curves (AUC) with 173 their 95%Cls [13]. Discrimination is usually considered as null when the AUC is 0.5, poor when 174 between 0.5 and 0.7, satisfactory between 0.7 and 0.8, good between 0.8 and 0.9, excellent between 175 0.9 and 1, and perfect when the AUC equals 1. In addition, we provided classification plots to assess 176 the discriminative ability of COVIDENGUE scores conditional to absolute risk thresholds [14]. Finally, 177 scores performances were internally validated by using bootstrapping (2000 replicates).

178 The calibration of the COVIDENGUE scores (*i.e.*, the adequacy between predicted and 179 observed events) was evaluated using state-of-art calibration plots [15] and Hosmer-Lemeshow tests

180 for MLR and binomial logistic regression models [12,16], as well as with event-based or risk-based

181 calibration plots which were displayed over the range of MHL deciles of predicted risks.

The diagnostic performance of each COVIDENGUE score cut-off was displayed in terms of sensitivity, specificity, positive likelihood ratio (LR+), negative likelihood ratio (LR-), positive predictive value (PPV), negative predictive value (NPV) and diagnostic accuracy. For all these analyses, observations with missing data were ruled out, tests were two-tailed,

- and a *P*-value less than 0.05 was considered as statistically significant.
- 187 The full details of the methods can be found in the text file S1. The results were reported
- 188 following both the STROBE and TRIPOD reporting guidelines for observational studies and prediction
- 189 models (text file S2), respectively [17,18].

190 **Results**

191 Characteristics of the study population

192 Between 23 March and 10 May 2020, 1,715 subjects were admitted to the UDACS for screening for

193 or diagnosis of COVID-19. Over this 6-week period, the lab did not diagnose any cocirculation of

194 influenza or non-influenza respiratory viruses.

As part of an expanded screening week dedicated to all admissions to our hospital, 370

subjects who were screened opportunistically and 332 fully asymptomatic subjects were ruled out

197 leaving 1,013 outpatients eligible for this analysis. The study population is shown in Figure 1.

198 The characteristics of the 1,013 of patients who consulted the COVID-19 screening center during the

199 COVID-19 dengue co-epidemics are presented in S2 Table.

200 COVID-19 was diagnosed in 80 patients (7.9%) and dengue in 61 patients (6.0%) while 872 201 patients tested negative and were clinically considered as non-COVID-19, non-dengue subjects. 202 Interestingly, COVID-19 patients presented themselves later in the course of the illness compared to 203 patients with dengue or OFIs (time elapsed since symptom onset, 7.5 days versus 4.2 days or 6.3 204 days, P<0.001). Dengue was more likely to be symptomatic than COVID-19 as exemplified by higher 205 frequencies of fever, body ache, gut symptoms, fatigue, headache, and retro-orbital pain, as well as a 206 higher need for physical examination. However, COVID-19 exhibited longer durations of fatigue and 207 rhinorrhea.

208

209 Bivariate and multivariate analyses

210 The crude relationships between the sociodemographic, epidemiological, and clinical characteristics

211 in cases of COVID-19, dengue and OFIs are presented in S3 Table.

Bivariable analysis identified anosmia, the return from travel abroad during the previous 15 days, contact with a COVID-19 positive case and delayed presentation (beyond three days since symptom onset) as candidate predictors for COVID-19, whereas healthcare workers and active smokers as those protected against COVID-19. Headache, retro-orbital pain, body ache, fatigue, gut

symptoms, and previous individual episode of dengue were potential predictors for dengue, while the recent return from travel abroad and cough were potential protective factors against dengue. Interestingly, Upper Respiratory Tract Infection (URTI) symptoms provided protection against both infections (which means they were associated with OFIs), while the role of fever and ageusia was less clear, these being associated with both diagnoses of interest (S3 Table).

221 The variables that were significant in the bivariable analysis were entered into a full 222 multivariable MLR model (S4 Table). This generated 4% of missing observations (n=46). It supported 223 the role of anosmia, contact with a COVID-19 positive case and recent return from travel abroad as 224 independent predictors of COVID-19 as well as an association of active smokers to protection against 225 COVID-19. In turn, previous individual episodes of dengue, body ache, headache and retro-orbital 226 pain were independent predictors of dengue, while cough was less likely to be observed with this 227 infection. As for the bivariable analysis, URTI symptoms were indicative of OFIs. Alternatively, fever 228 proved non discriminant even though it was far more common with dengue which motivated its 229 exclusion from further analyses. As in our previous analysis [9], these findings were contrasted by the 230 weighting on the inverse probability of hospitalization rates (S5 Table).

After multicollinearity analysis, control of overfitting and unnecessary adjustments, the best fit MLR compromise model (based on AIC and BIC metrics) included eleven covariates (Table 1). This confirmed the role of anosmia, contact with a COVID-19 positive case and/or recent return from travel abroad as independent predictors of COVID-19, as well as the role of body ache, headache, previous individual episode of dengue and retro-orbital pain as predictors of dengue. Conversely, in this model, active smoking, cough, and URTI symptoms were considered as protective factors against COVID-19, dengue, or both.

Goodness-of-fit and discrimination indicators of the MLR models are displayed in S6 Table. We made the assumption that the best fit compromise model could be achieved with the eleven abovementioned covariates. The AUCs of the model were of 0.80 (95%CI 0.74-0.86) for COVID-19 and 0.89 (95%CI 0.84-0.92) for dengue in the primary analysis (Figure 2, panel a), and of 0.80 (95%CI

242 0.73-0.86) and 0.88 (95%Cl 0.84-0.92) after bootstrapping, respectively. Further adjustment on both

- age and/or gender did not improve the AUC of the model to a point sufficient enough to change
- 244 interpretation when considering AUC boundaries (S6 Table).
- 245
- 246 Score development and internal validation

247 Based on this final model, we derived two COVIDENGUE scores. For a better appropriation, we 248 decided to set the weight of each dengue clinical criterion at 5 points. With this exception, the 249 weighting scale was as described in S1 Table.

The translation of the final MLR model into two COVIDENGUE scores was satisfactory. This step showed barely a 1-point loss in the discriminative ability for both COVID-19 and dengue and a superimposition of model and score ROC plots (Figure 2, panel b and panel c).

253 The median value of the COVID-19 score was 1 (Q_1 - Q_3 : 0 to 3, range: -4 to 14) and the median 254 value of the dengue score was 3 (Q_1 - Q_3 : -1 to 7, range: -4 to 18). In the primary analysis, the 255 discriminative ability of the scores was satisfactory to good for COVID-19 (AUC 0.79, 95%CI 0.76-0.82) 256 and good for dengue (AUC 0.88, 95%Cl 0.85-0.90) (Figure 2, panel d). Interestingly, the dengue score 257 exhibited higher true positive rates than the COVID-19 score (which means false negative cost was 258 minimized versus the false positive cost) in risk thresholds higher than 0.4. COVID-19 had higher 259 false positive rates in risk thresholds under 0.5 than the dengue scores (which means FP cost was 260 minimized versus FN) (S1 Fig.).

After bootstrapping, when considering confidence intervals, the discriminative ability was between poor and good for COVID-19 (AUC 0.75, 95%Cl 0.68-0.82) and good for dengue (AUC 0.86, 95%Cl 0.81-0.90), which represented an AUC loss of five points and three points from the final MLR model, respectively.

Overall, the calibration of the COVIDENGUE scores as shown by calibration plots (S1 Fig.) and MHL tests (S7 Table and S8 Table) was deemed satisfactory albeit prone to underfitting for COVID-19 (slope: 1.22, intercept 0.08; chi2 (6) 1.75, *P*=0.9416), whereas it was excellent and consensual for

dengue (slope: 0.97, intercept 0.12; chi2 (8) 6.78, *P*=0.5605). Strikingly, despite few discrepancies between predicted and observed events (S2 Fig. and S3 Fig., panel a and panel c), and a trend towards underprediction of COVID-19 events (S4 Fig., panel a), the MHL test of both COVIDENGUE scores was well balanced across the deciles of predicted risks (S7 Table and S8 Table) and their calibration displayed other metrics better than those of the reference model (S9 Table).

273 For overall COVID-19 prediction, a threshold of 0 points displayed a sensitivity of 97.3% (95%CI 274 96.2%-98.3%) and a NPV of 99.0% (95%Cl 98.4%-99.6%), while a threshold of 10 points displayed a 275 specificity of 98.8% (95%CI 98.1%-99.5%) and a PPV of 65.1% (95%CI 62.1%-68.1%). A 3-point cut-off 276 maximized both sensitivity and specificity (78.1% and 63.7%, respectively). Regardless of COVID-19 277 prevalence, the COVID-19 score was effective in excluding COVID-19 (LR- <0.10) for negative score 278 values under -1, whereas it was effective for diagnosing COVID-19 (LR+ >10) with score values higher 279 than 7. The detailed performances of the COVID-19 score are presented in S10 Table, its intrinsic and 280 extrinsic properties in Figure 3 (Panel a to panel d). For COVID-19 individual risk prediction, the 281 estimated probability of being infected derived from the COVID-19 score was $Prob_{(Y=1/x)} = 1 / (1 + exp^{-1})$ (-3.698086 + 0.3533028 X score value) 282

283 For dengue overall prediction, a threshold of 3 points displayed a sensitivity of 96.7% (95%CI 284 95.5%-97.8%) and a NPV of 99.7% (95%Cl 99.4%-100%) while a threshold of 11 points displayed a 285 specificity of 97.7% (95%CI 96.7%-98.6%) and PPV of 40.3% (95%CI 37.2%-43.3%). A 6-point cut-off 286 maximized both sensitivity and specificity (83.3% and 71.7%, respectively). Regardless of dengue 287 prevalence, the dengue score was effective in excluding dengue (LR- <0.10) for score values under 4, 288 whereas it was effective for diagnosing dengue (LR + >10) with score values higher than 10. The 289 detailed performances of the dengue score are presented in S11 Table, its intrinsic and extrinsic 290 properties in Figure 3 (Panel a to panel d). For dengue individual risk prediction, the estimated probability of being infected derived from the dengue score was $Prob_{(Y=1/x)} = 1 / (1 + exp^{-(-5.508826 + 1/x)})$ 291 0.4406125 X score value)). 292

293 Discussion

294 In this study, COVIDENGUE scores were developed and internally validated. An eleven covariate-295 based prediction model aimed at distinguishing COVID-19 from dengue and other febrile illnesses at 296 their clinical onset was made in the context of cocirculation of SARS-CoV-2 and DENV. Overall, the 297 predictive performance of the score, meaning the ability to diagnose or to rule out infection, was 298 good for dengue and satisfactory for COVID-19, while calibration performance meaning the ability to 299 minimize the discrepancy between expected and observed events, was at least satisfactory on 300 multiple metrics of goodness-of-fit statistics. The dengue score for which symptoms were good 301 predictors, displayed both better sensitivity and a higher negative predictive value while the COVID-302 19 score for which risk factors were paramount, proved more specific and had a higher positive 303 predictive value across the whole range of cut-offs.

304

305 Strengths and limitations

306 A scoring system should have both construct and content validity. It must be able to be reproduced 307 over time and across geographic and methodological boundaries. It must also be accurate 308 (calibration and discrimination) and clinically meaningful [19]. Before this study, we previously 309 assumed that COVID-19 and dengue diagnoses could be affected by a misclassification bias which 310 could stem from the poor sensitivity of both SARS-CoV-2 molecular and DENV NS1 antigen tests 311 rather than from their false positives [9]. This putative bias was believed to be minimal given that, 312 firstly, on Reunion Island, like anywhere else during the rise of the COVID-19 pandemic [20], there 313 was little cocirculation of other respiratory viruses that could have competed with SARS-CoV-2 and 314 caused false negatives, [21] and secondly, for COVID-19, negative samples were retested by RT-PCR 315 upon onset of new symptoms, meaning that rapid antibody or antigenic tests were ruled out, while 316 for dengue, the workup was completed by a RT-PCR or a serology test to downsize false negative and 317 false positive proportions [22-24]. This caution decision rule likely pledges the diagnostic accuracy of 318 our gold standards.

Interestingly, the calibration of both scores was satisfactory to excellent and displayed measures close to the theoretical model from which they were derived based on a set of various goodness-of-fit metrics. Notwithstanding a relatively small study population, the diagnostic accuracy of gold standards, along with the acceptable calibration properties ensure the validity of construct of the COVIDENGUE scores and the reliability of their predictions at the individual level for the dengue score, while, together with their discriminative ability, also lend support to their clinical utility [25].

325 The COVIDENGUE scores were developed using MLR [9] which is the gold standard method for 326 assessing non-ordered polytomous categorical outcomes [26,27]. Except for active smoking whose 327 protective effect against SARS-CoV-2 infection remains a matter of debate among researchers 328 [28,29], all predictors retained to build the scores had been previously identified as relevant 329 indicators of COVID-19 or dengue or associated with OFIs (especially respiratory infections) [29-40] 330 This ensures both the validity of content of this scoring system and the possibility of contrasted 331 predictions. For example, international travel had been identified as a source of COVID-19 during the 332 first pandemic wave [34,35]. In a recent Colombian study [38], dengue proved more symptomatic 333 than COVID-19 and dengue patients came to the hospital in greater numbers than COVID-19 334 patients. In Brazil's Amazonian basin, prior to a dengue infection, as diagnosed by positive IgG 335 antibodies was associated with twice the risk of clinically apparent COVID-19 [36]. The external 336 validity of the other predictors has been discussed thoroughly in our previous study [9]. Interestingly, 337 similar to our first analysis, weighting on the inverse odds of hospitalization abrogated the 338 significance of a few predictors (Table 1 versus S5 Table), which suggests a contrast in our findings at 339 the population level and motivates further validation studies in the primary care setting.

Notably, this hospital-based study was conducted in a SARS-CoV-2 screening center which may have underestimated the real incidence of dengue and introduced another information bias in that dengue patients could have been potentially directed towards other units or even underreported given the lack of epidemiological predictors reported for dengue [9]. This potential limitation of the validity of content should be investigated in future studies by adding more risk factors for dengue to

refine our models. Lastly, our scoring system was composed of only clinical and epidemiological criteria. It was user-friendly for diagnosis purposes which should facilitate its utilization across different settings while also helping its external validation.

348

349 Interpretation

350 For epidemiological and clinical practices, the overall performance of a prediction model relies first 351 on its discrimination [13]. In this perspective, ROC plots do not offer more information than the AUC 352 to indicate the discriminative ability [13,14]. In this study, we demonstrated that the discriminative 353 ability of the models could be improved only at the unreasonable cost of complexity (20-item model), 354 or when adding age to the COVID-19 model; a factor whose effect might change according to the 355 context (S6 Table). This study also showed that the translation of the model into two scores was not 356 accompanied by a significant loss in discriminative ability (Figure 2) which suggests an adequate 357 weighting of the scores.

358 Importantly, we provided classification plots which may offer more information for decision-359 making conditional to risk thresholds [13,14]. Overall, classification plots may reveal a better ability 360 of the COVID-19 score to predict non-events (OFIs) and a better ability of dengue score to predict 361 events (dengue). Moreover, at lower risk thresholds the COVID-19 score exhibited a lower cost of FP 362 than the dengue score. For example, when the event risk was 0.2, the COVID-19 score yielded a 0.5:1 363 FN to FP ratio while it was 1:1 for the dengue score (Figure S1). These results aligned with a trend 364 towards a better specificity for the COVID-19 score than for the dengue score across the range of cut-365 off values (Figure 3). Conversely, at higher risk thresholds (>0.5), when it came to predict an event, 366 the dengue score displayed a better sensitivity (in other words, higher TP rate, or a lower cost of FN 367 versus FP cost). Taken together with respect to the SARS-CoV-2 strategy of testing, isolating, and 368 tracing, our findings encourage evaluating the addition of clinical or biological discriminative 369 variables [38,39] in the COVID-19 score to improve its sensitivity across the risk thresholds while in 370 regard to the dengue strategy of testing, isolating, and targeted vector control, they encourage the

371 fitting with more specific epidemiological variables highly predictive of an infective bite by an *Aedes*

372 mosquito.

At an individual risk level, predictions should be guided using first of all calibration performances (calibration plots and goodness-of-fit metrics) [24]. Our findings showed that the calibration of the models (Table S6 to S8) and their derived scores (Table S9) were excellent and consensual for dengue which enables individual risk prediction and satisfactory for COVID-19 which suggests caution for individual risk prediction.

378

379 Generalizability

380 The COVIDENGUE scores were developed from data acquired within a hospital-based SARS-CoV-2 381 testing center on Reunion Island which is a tropical setting where dengue co-circulated early on 382 during the first pandemic wave at a time when there was no possibility to screen for COVID-19 383 outside the hospital. The circulation of the SARS-CoV-2 variant was furthermore unknown and the 384 population of infected people were mainly composed of relatively healthy travelers [9,35]. Thus, 385 although our center served an ambulatory healthcare driven population, the scores will have to be 386 validated in primary care settings before being broadly used in the community. They will also have to 387 be validated in the highly comorbid autochthonous population of the island [9,35].

388 In future research, the scores should be studied in the context of newly circulating SARS-CoV-2 389 variants as well as in the context of populations immunized against dengue or COVID-19. On Reunion 390 Island, the first wave of SARS-CoV-2 circulation ended in June 2020 as a result of the influence of the first national lockdown. The second wave began in August 2020 during the winter season of the 391 392 region and was concomitant to the spread of the D614G mutation in Europe [7]. Since this period, 393 SARS-CoV-2 transmission has been mainly autochthonous and successively maintained through the 394 circulation of both South African (B.1.351/501Y.V2) and the Indian (B.1.617/21APR-02) variants of 395 concerns (VOCs). While the clinical presentation of dengue appears to be different between DENV-2 396 and DENV-1 serotype infections (DENV-1 has been predominant on the island since 2020) on top of

the proportions of secondary infections [41], it is not yet clear whether the prevalence of COVID-19 has changed throughout the circulating VOCs despite a trend towards increased severity reported with the UK (B.1.1.7/501Y.V1) [42], along with the Brazilian (P.1/501Y.V3) [43], South African [44], or lndian variants [45]. The same could be said to the potential for more clinically apparent manifestations of COVID-19 when DENV infection precedes SARS-CoV-2 infection [36] as well as the potential for higher severity with SARS-CoV-2 DENV co-infections [2]. Both have to be fully investigated in the future with the diagnostic value of the COVIDENGUE scores evaluated.

404

405 Implications

For individual risk prediction and clinical practice, the equations of estimated probability of being diagnosed as infected derived from the scores could be used to define individual risks conditional to adequate calibration. Herein, we have shown that the COVIDENGUE scores could be useful to diagnose dengue patients in a tropical SARS-CoV-2 screening center, however they deserved further improvements for diagnosing COVID-19.

411 For public health purposes, the score values could be incorporated into testing strategies and 412 guided with mitigation interventions whenever routine biological testing is ineffective. For clinical 413 research, the cut-off values could serve to risk stratification in new diagnostic studies and the 414 COVIDENGUE scores items incorporated into propensity scores. For benchmarking of prediction 415 models, the predicted risk probabilities of a new model could also be summed up and compared to 416 the total number of infected individuals (to define risk thresholds) under the assumption that such an 417 observed-to-predicted risk ratio together with the slope of the calibration plots and the Hosmer-418 Lemeshow chi2 test probability, would be close to one, to underlie the adequate calibration of the 419 new model.

420 When it comes to testing the external validity of the COVIDENGUE scores in a different 421 epidemiological context, or to improving their predictive performances by adding or removing 422 variables within a new model, investigators will have to consider using calibration plots and

423	goodness-of-fit statistics to see whether the model is properly calibrated and could apply to
424	individual risk prediction. Such novel investigations should delve deeper into demonstrating the
425	clinical use while providing new indicators such as the IDI (Integrated Discrimination Improvement)
426	and/or the net benefit from classification plots or decision curve analyses [13,14].
427	
428	Conclusions
429	In conclusion, the COVIDENGUE scores proved discriminant to differentiate COVID-19 and dengue
430	from OFIs in the context of SARS-CoV-2 testing center during a co-epidemic. Further studies are
431	needed to validate or refine these scores in other settings.
432	
433	Acknowledgments
434	The authors are indebted to the staffs of the Department of Infectious Diseases and Tropical
435	Medicine, especially Dr Yatrika Koumar, and the SARS-CoV-2 testing center with special appreciation
436	given to Dr Antoine Joubert and the nurses who performed the questionnaires. The authors would
437	also like to thank the biologists at CHU de La Réunion for their timely diagnosis, the participants for
438	their interest in research and AcaciaTools for their reviewing and medical writing services.

439 **Supporting information**

440	Supplementary material is available online. While the supplementary tables have been copyedited,
441	the methodological appendix and the Venn diagram have not been copyedited and are the sole
442	responsibility of the authors. Questions and comments about these should be addressed to the
443	corresponding author. STROBE and TRIPOD checklists (text file S2).

444

445 **Notes**

446 Author's contributions.

447 Conceptualization: Fanny Andry, Patrick Gérardin, Cécile Levin. Data curation: Patrick Gérardin. 448 Formal analysis: Patrick Gérardin, Antoine Bertolotti, Olivier Maillard, Léa Bruneau, Cécile Levin. 449 Investigation: Frédéric Accot, Florian Legrand, Patrice Poubeau, Rodolphe Manaquin, Fanny Andry, 450 Antoine Bertolotti, Cécile Levin. Methodology: Patrick Gérardin. Project administration: Fanny Andry. 451 Resources: Cécile Levin. Software: Patrick Gérardin. Supervision: Olivier Maillard, Antoine Bertolotti. 452 Validation: Patrick Gérardin, Cécile Levin, Visualization: Patrick Gérardin, Writing – original draft: 453 Patrick Gérardin. Writing – review & editing: Patrick Gérardin, Olivier Maillard, Léa Bruneau, Frédéric 454 Accot, Florian Legrand, Patrice Poubeau, Rodolphe Manaquin, Fanny Andry, Antoine Bertolotti and 455 Cécile Levin. 456

- 450
- 457 List of abbreviations (alphabetic order)
- 458 **aOR:** Adjusted odds ratio
- 459 **AUC**: Area under receiver operating characteristic curve
- 460 **CIR:** Cumulative incidence rate (attack rate)
- 461 **CNR**: Centre national de reference
- 462 COVID-19: Coronavirus 2019
- 463 **DENV:** Dengue virus
- 464 ICU: Intensive Care Unit

- 465 MHL test: Multinomial Hosmer-Lemeshow test
- 466 MLR: Multinomial logistic regression
- 467 **OFIs:** Other febrile illnesses
- 468 **RT-PCR**: Reverse transcription polymerase chain reaction
- 469 SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2
- 470 **SpO2**: Pulse oxymetry
- 471 UDACS: Unite de dépistage ambulatoire du coronavirus sud
- 472 URTI: Upper respiratory tract infection
- 473 **VOCs**: variants of concerns
- 474 **95% CI:** 95% confidence interval
- 475
- 476 Funding: None
- 477
- 478 **Potential conflicts of interest:** All authors would like to report that there are no conflicts of interest
- in relation to this research. All authors have signed the ICMJE disclosure form for potential conflicts
- 480 of interest.
- 481
- 482 **Data availability statement:** Data are entirely accessible through a data repository through the 483 publication of this article.
- 484

485 **References**

 Caron M, Paupy C, Grard G, Becquart P, Mombo I, Nso BB, et al. Recent introduction and rapid dissemination of Chikungunya virus and Dengue virus serotype 2 associated with human and mosquito coinfections in Gabon, central Africa. Clin Infect Dis 2012; 55: e45-53. http://dx.doi:10.1093/cid/cis530. Epub 2012 Jun 5.

490 2. Mejia-Parra JL, Aguilar-Martinez S, Fernandez-Mogollon JL, Luna C, Bonilla-Aldana DK, 491 Rodriguez-Morales AJ, et al. Characteristics of patients coinfected with Severe Acute Respiratory 492 Syndrome Coronavirus 2 and dengue virus, Lambayeque, Peru, May-August 2020: A 493 retrospective analysis. Travel Med Infect Dis 2021; 43: 102132. 494 https://dx.doi/10.1016/j.tmaid.2021.102132. Epub 2021 Jun 26.

Huang SY, Lee IK, Wang L, Liu JW, Hung SC, Chen CC, et al. Use of simple clinical and
laboratory predictors to differentiate influenza from dengue and other febrile illnesses in
the emergency room. BMC Infect Dis 2014; 14: 623. http://dx.doi:10.1186/s12879-0140623-z.

- 499 4. Wilder-Smith A, Tissera H, Ooi EE, Coloma J, Scott TW, Gubler DJ. Preventing dengue
 500 epidemics during COVID-19 pandemic. Am J Trop Med Hyg 2020; 103: 570-571.
 501 http://dx.doi: 10.4269/ajtmh.20-0480.
- 502 5. Gérardin P, Guernier V, Perrau J, Fianu A, Le Roux K, Grivard P, et al. Estimating
 503 Chikungunya prevalence in La Réunion island outbreak by serosurveys: two methods for
 504 two critical times of the epidemic BMC Infect Dis 2008; 8: 99. http://dx.doi:10.1186/1471 505 2334-8-99.
- 506 6. Vincent M, Larrieu S, Vilain P, Etienne A, Solet JL, François C, et al. From the threat to
 507 the large outbreak: dengue on Reunion island. Euro Surveill 2019; 24: 1900346.
 508 http://dx.doi: 10.2807/1560-7917.ES.2019.24.47.1900346.
- 7. Wilkinson DA, Lebarbenchon C, Atyame C, Hafsia S, Jaffar-Bandjee MC, Menudier-Yemandja L, et
 al. Genomic insights into early SARS-CoV-2 strains isolated in Reunion Island. MedRxiv 2021 Jan
 6. https://doi.org/10.1101/2021.01.21.21249623.
- Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, et al. Prediction
 models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ
 2020;369:m1328. https://dx.doi.org/10.1136/bmj.m1328.
- Joubert A, Andry F, Bertolotti A, Accot F, Koumar Y, Legrand F, et al. Distinguishing non
 severe cases of dengue from COVID-19 in the context of co-epidemics: a cohort study in

a SARS-CoV-2 testing center on Reunion island. PLoS Negl Trop Dis 2021; 15:

- 518 e0008879. https://dx.doi/10.1371/journal.pntd.8879.
- 519 10. Leening MJG, Steyerberg EW, Van Calster B, D'Agostino RB, Pencina MJ. Net reclassification
- 520 improvement and integrated discrimination improvement require calibrated models: relevance
- 521 from a marker and a model perspective. Stat Med 2014; 33: 3415-8. https://dx.doi/10.
- 522 1002/sim.6133.
- 11. Marty FM, Chen K, Verrill KA. How to obtain a nasopharyngeal swab specimen. New Engl J Med
 2020; 382; e76. https://dx.doi/10.1056/NEJMvcm2010260.
- 525 12. Fagerland MW, Hosmer DW. A generalized Hosmer-Lemeshow goodness-of-fit test for
 526 multinomial logistic regression models. Stata Journal 2012; 12: 447-53.
 527 https://dx.doi/10.1177/1536867X1201200307.
- Verbackel JY, Steyerberg EW, Uno H, De Cock B, Wynants L, Collins GS, et al. ROC curves for
 clinical prediction models part 1. ROC plots showed no added value to the AUC when evaluating
 the performance of clinical prediction models. J Clin Epidemiol 2020; 126: 207-15.
 https://dx.doi/10.1016/j.clinepi.2020.01.028.
- Van Calster B, Wynants L, Collins GS, Verbackel JY, Steyerberg EW. ROC curves for clinical
 prediction models part 3. The ROC plot: a picture that needs a 1000 words. J Clin Epidemiol
 2020; 126: 220-3. https://dx.doi/10.1016/j.clinepi.2020.05.037.
- 15. Van Calster B, Nieboer D, Vergouwe Y, De Cock B, Pencina MJ, Steyerberg EW. A calibration
 hierarchy for risk models was defined: from utopia to empirical data. Stat Med 2016; 74: 167-76.
 https://dx.doi/10.1016/j.jclinepi.2015.12.005.
- Lemeshow S, Hosmer DW. A review of goodness of fit statistics for use in the development of
 logistic regression models. Am J Epidemiol 1982; 115: 92–8.
 https://dx.doi/10.1093/oxfordjournals.aje.a113284.
- 541 17. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative.
 542 The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)

543 statement: guidelines for reporting observational studies. PLoS Med 2007; 4: e296.

- 544 https://dx.doi/10.1371/journal.pmed.0040296.
- 54518. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable546prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. BMC
- 547 Med 2015; 13: 1. https://dx.doi/10.1186/s12916-014-0241-z.
- 548 19. Leteurtre S, Martinot A, Duhamel A, Proulx F, Grandbastien B, Cotting J, et al. Validation of the
- 549 paediatric logistic organ dysfunction (PELOD) score: prospective, observational, multicentre
- 550 study. Lancet 2003; 362: 192-7. https://dx.doi/10.1016/S0140-6736(03)13908-6.
- 551 20. Nowak MD, Sordillo EM, Gitman MR, Paniz-Mondolfi AE. Coinfection in SARS-CoV-2 infected
- patients: Where are influenza virus and rhinovirus/enterovirus? J Med Virol 2020; 92: 1699-
- 553 1700. https://dx.doi/10.1002/jmv.25953. Epub 2020 Jul 17.
- 554 21. Jin-Jung Y, Campèse C, Lévy-Bruhl D, Savitch Y; Santé Publique France. Grippe: bilan de la saison
 555 2019-2020. Chêne G ed: 2020 Oct 13; 10: 1-10. https://www.santepubliquefrance.fr/maladies-
- 556 et-traumatismes/maladies-et-infections-respiratoires/grippe/documents/bulletin-

557 national/bulletin-epidemiologique-grippe.-bilan-de-la-surveillance-saison-2019-2020.

- 558 22. Lokida D, Lukman N, Salim G, Butar-butar DP, Kosasih H, Wulan WN, et al. Diagnosis of COVID-19
- 559 in a dengue-endemic area. Am J Trop Med Hyg. 2020; 10: 1220-2. https://dx.doi/
 560 10.4269/ajtmh.20-0676.
- 23. Vanroye F, Van den Bossche D, Brosius I, Tack B, Van Esbroek M, Jacobs J. COVID-19 antibody
 detecting rapid diagnostic tests show high cross-reactivity when challenged with pre-pandemic
 malaria, schistosomiasis and dengue samples. Diagnostics (Basel) 2021; 11: 1163. https://dx.doi/
 10.3390/diagnostics11071163.
- 565 24. Khandker SS, Nik Hashim NHH, Deris ZZ, Shueb RH, Islam MA. Diagnostic accuracy of rapid
 566 antigen test kits for detecting SARS-CoV-2: a systematic review and meta-analysis of 17,171
 567 suspected COVID-19 patients. J Clin Med 2021; 10: 3493. https://dx.doi/10.3390/jcm10163493.

568 25. Van Calster B, Steyerberg EW, Harrell FH. Risk prediction for individuals. JAMA 2015; 314: 1875.

569 https://dx.doi/10.1001/jama.2015.12215.

- 570 26. Van Calster B, Vergouwe Y, Looman CWN, Van Belle V, Timmerman D, Steyerberg EW. Assessing
- 571 the discriminative ability of risk models for more than two outcome categories. Eur J Epidemiol
- 572 2012; 27: 761–70. https://dx.doi/10.1007/s10654-012-9733-3.
- 573 27. Van Hoorde K, Vergouwe Y, Timmerman D, Van Huffel S, Steyerberg EW, Van Calster B.
- Assessing calibration of multinomial risk prediction models. Stat Med 2014; 33: 2585-96.
 https://dx.doi/10.1002/sim.6114.
- 576 28. Usman MS, Siddiqi TJ, Khan MS, Patel UK, Shahid I, Ahmed J, et al. Is there a smoker's paradox in
 577 COVID-19? BMJ Evid Based Med. 2020 Aug 11:bmjebm-2020-111492.
 578 https://dx.doi/10.1136/bmjebm-2020-111492. Online ahead of print.
- 29. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ, COVID-19 Systematic Urgent Review
 Group Effort (SURGE) Study Authors. Physical distancing, face masks, and eye protection to
 prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and
 meta-analysis. Lancet 2020; 395: 1973-87. https://dx.doi/0.1016/S0140-6736(20)31142-9. Epub
 2020 Jun 1.
- 30. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM et al. Occurrence and
 transmission potential of asymptomatic and presymptomatic SARSCoV-2 infections: A living
 systematic review and meta-analysis. PLoS Med. 2020; 17: e1003346. https://dx.doi/
 10.1371/journal.pmed.1003346. eCollection 2020 Sep.
- 31. Premaratna R, Pathmeswaran A, Amarasekara NDDM, Motha MBC, Perera KVHKK, de Silva HJ. A
 clinical guide for early detection of dengue fever and timing of investigations to detect patients
 likely to develop complications. Trans R Soc Trop Med Hyg 2009;103: 127-31. https://dx.doi/10.
 1016/j.trstmh.2008.07.024.
- 592 32. Riddell A, Babiker ZO. Imported dengue fever in East London: a 6-year retrospective 593 observational study. J Travel Med 2017; 24: 1-6. https://dx.doi/10.1093/jtm/tax015.

- 59433. El-Anwar MW, Eesa M, Mansour W, Zake LG, Hendawy E. Analysis of Ear, Nose and Throat595Manifestations in COVID-19 Patients. Int Arch Otorhinolaryngol. 2021; 25: e343-e348.
- 596 https://dx.doi/10.1055/s-0041-1730456.
- 597 34. Gu W, Deng X, Reyes K, Hsu E, Wang C, Sotomayor-Gonzalez A, et al. Associations of early
- 598 COVID-19 cases in San Francisco with domestic and international travel. Clin Infect Dis 2020; 71:
- 599 2976-80. https://dx.doi/10.1093/cid/ciaa599.
- Krol P, Coolen-Allou N, Teysseyre L, Traversier N, Beasley F, Nativel M, et al. Differential
 diagnoses of severe COVID-19 in tropical areas: the experience of Reunion Island. Trop Med Int
 Health 2021; 26: 444-52. https://dx.doi/10.1111/tmi.13542.
- 603 36. Nicolete VC, Rodrigues PT, Johansen IC, Corder RM, Tonini J, Cardoso MA et al. Interacting 604 epidemics in Amazonian Brazil: prior dengue infection associated with increased COVID-19 risk 605 population-based in а cohort study. Clin Infect Dis 2021; ciab410. 606 https://dx.doi/10.1093/cid/ciab410. Online ahead of print.
- Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2
 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with
 Bayesian analyses (version 7). Addiction 2021; 116: 1319-68. https://dx.doi/10.1111/add.15276.
 Epub 2020 Nov 17.
- 38. Romero-Gameros CA, Colin-Martínez T, Waizel-Haiat S, Vargas-Ortega G, Ferat-Osorio E,
 Guerrero-Paz JA, et al. Diagnostic accuracy of symptoms as a diagnostic tool for SARS-CoV 2
 infection: a cross-sectional study in a cohort of 2,173 patients. BMC Infect Dis. 2021; 21: 255.
 https://dx.doi/10.1186/s12879-021-05930-1.
- 39. Rosso F, Parra-Lara LG, Agudelo-Rojas OL, Martinez-Ruiz DM. Differentiating dengue from
 COVID-19: comparison of cases in Colombia. Am J Trop Med Hyg 2021; tpmd200912.
 https://dx.doi/10.4269/ajtmh.20-0912. Online ahead of print.

- 618 40. Ruiy W, Hsu SY, Tsai HL, CT Chen. COVID-19 mimicking dengue fever with the initial
- 619 manifestation of retro-orbital pain a rare case. J Formos Med Assoc 2020; 119: 1715-16.
- 620 https://dx.doi/10.1016/j.jfma.2020.05.039. Epub 2020 Jun 4.
- 41. Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Haldstead SB. Dengue infection. Nat Rev Dis
- 622 Primers 2016; 2: 16055. https://dx.doi/10.1038/nrdp.2016.55.
- 42. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality
- 624 in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ
- 625 2021; 372: n579. https://dx.doi/10.1136/bmj.n579.
- 43. Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DdS, Mishra S, et al. Genomics and
 epidemiology of the P1.SARS-CoV-2 lineage in Manaus, Brazil. Science 2021; 372(6544): 815-21.
- 628 https://dx.doi/10.1126/science.abh.2644. Epub 2021 Apr 14.
- 44. Puech B, Legrand A, Simon O, Combe C, Jaffar-Bandjee MC, Caron M, et al. Prognosis of
 critically-ill patients with acute respiratory failure due to SARS-CoV-2 (501Y.V2) variant: a
 multicenter retrospective matched cohort study. Research Square 2021. https://dx.doi/
 10.21203/rs.3.rs-80608v2.
- 633 45. Ong SWX, Chiew CJ, Ang LW, Mak TM, Cui L, Toh MPHS, et al. Clinical and virological features of 634 SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 635 B.1.617.2 (Delta). Clin Infect Dis 2021; ciab721. https://dx.doi/ (Beta), and 636 10.1093/cid/ciab721. Online ahead of print.

Table 1. Final best fit multinomial logistic regression model distinguishing the independent predictors of COVID-19 and dengue from those of other febrile illnesses among 969 participants who consulted at a COVID-19 screening center in Saint Pierre (Reunion Island) during the COVID-19 dengue co-epidemics from 23 March to 10 May 2020

Outcomes (versus other febrile illnesses as controls*)	COVID-19 (N = 73)				Dengue (N = 60)				
Predictors	n	CIR, (%)	aOR	95% CI	Points	n	CIR, (%)	aOR	95% CI	Points
Contact with a COVID-19 positive case		15.38	4.26	2.33 to 7.78	+ 3	6	2.31	0.71	0.26 to 1.87	0
Return from travel abroad < 15 days		16.03	3.53	2.05 to 6.05	+ 3	6	2.53	0.41	0.15 to 1.05	- 1
Previous individual episode of dengue		9.06	2.16	0.56 to 8.29	+ 1	9	20.45	4.50	1.68 to 12.00	+ 3
Active smoker †		2.53	0.25	0.09 to 0.67	- 3	12	7.59	1.38	0.65 to 2.91	0
Cough	32	6.82	0.95	0.53 to 1.68	0	17	3.62	0.36	0.18 to 0.70	- 2
Body ache [‡]	29	7.09	1.26	0.70 to 2.24	0	52	12.71	6.35	2.56 to 15.71	+ 5
Anosmia	26	27.96	7.64	4.13 to 14.12	+ 7	3	3.23	0.47	0.11 to 2.01	- 1
Headache	28	5.70	0.92	0.54 to 1.55	0	55	11.20	5.51	1.85 to 16.41	+ 5
Retro-orbital pain		2.27	0.53	0.06 to 4.53	- 1	17	38.64	4.42	2.03 to 9.59	+ 5
Upper respiratory tract infection symptoms [#]		5.63	0.53	0.31 to 0.90	- 1	20	4.02	0.51	0.26 to 0.98	- 1
Presentation > 3 days after symptom onset		9.55	1.71	0.94 to 3.10	+ 1	24	4.32	0.75	0.39 to 1.42	0

Multinomial logistic regression model with other non COVID-19 non dengue febrile illnesses*, taken as controls. Data are numbers, cumulative incidence rates (CIR) expressed as percentages, adjusted odd ratios (aOR), 95% confidence intervals (95% CI). ⁺ Current smoker, as compared to never smoker and past smoker; [‡] muscle pain or backache with tightness and/or stiffness; [#] sore throat, runny nose, nasal congestion, or sneezing. 44 Participants with missing data excluded from the model (1013-969) of whom 42 had missing information on the delay of presentation, 1 on the return from travel abroad, 1 on a previous episode of dengue. The indicators of performance of the model are as follows: Bayesian information criterion -5709, Goodness of fit chi-2 test's probability 0.31, areas under the receiver operating characteristic curves 0.80 (95%CI 0.74-0.86) and 0.89 (95%CI 0.84-0.92), respectively. For COVID-19 prediction, the estimated probability of being infected is Prob (Y=1/x) = 1 / (1 + exp^{-(-.382 + $\sum_{i} j \times x_i)$) and the beta coefficients of the model are as follows: $\sum \beta_i \times X_j = 1.45 X_1 + 1.26 X_2 + 0.77 X_3 - 1.37 X_4 - 0.05 X_5 + 0.23 X_6 + 2.03 X_7 - 0.08 X_8 - 0.63 X_9 - 0.64 X_{10} + 0.54 X_{11}$ and intercept coefficient is - 3.82. For dengue prediction, the estimated probability of being infected is Prob $\frac{(V=1/x)}{(V=1/x)} = 1 / (1 + exp^{-(-.4.40 + \sum_{i} j \times x_i)}{1}$ and the beta coefficients of the model are as follows: $\sum \beta_i \times X_j = 1.45 X_1 + 1.26 X_2 + 0.77 X_3 - 1.37 X_4 - 0.05 X_5 + 0.23 X_6 + 2.03 X_7 - 0.08 X_8 - 0.63 X_9 - 0.64 X_{10} + 0.54 X_{11}$ and intercept coefficient is - 3.82. For dengue prediction, the estimated probability of being infected is Prob $\frac{(V=1/x)}{(V=1/x)} = 1 / (1 + exp^{-(-.4.40 + \sum_{i} j \times x_i)}{1}$ and the beta coefficients of the model are as follows: $\sum \beta_i \times X_j = -0.35 X_1 - 0.90 X_2 + 1.50 X_3 + 0.32 X_4 - 1.02 X_5 + 1.85 X_6 - 0.75 X_7 + 1.71 X_8 + 1.49 X_9 - 0.66 X_{10} - 0.29 X_{11}$ and intercept coefficient is - 4.40.}}}

Figures



Figure 1. Study population for differentiating dengue and COVID-19 from other febrile illnesses in co-

epidemics



Figure 2. Discriminative ability of the final model and of COVIDENGUE scores for COVID-19 and dengue at Saint-Pierre, Reunion Island from 23 March to 10 May 2020

Notes: Areas under receiver operating characteristic (AUC) curves are given for the best fit compromise final models (reference models) and the COVIDENGUE scores before validation by bootstrapping. The better the model or the score discriminates, the more the ROC curve approaches the upper left corner of the plot. A model with no discriminative ability has a true ROC curve that lies on the diagonal line.



Figure 3. Diagnostic performances of the COVIDENGUE scores





100 - Specificity (%)

100 - Specificity (%)



100 - Specificity (%)

